Metastatic prostate cancer with a normal prostate-specific antigen level

Clinical and Translational Oncology

Volumn 7, Issue 9, 2005, Pages 412-413

  Ruiz Martín, Isabel ^a   Rodríguez Sánchez, César A ^a   Ocaña Fernández, Alberto ^a   Del Valle Zapico, Javier ^a   De Prado Otero, Diego Soto ^a   Cruz Hernández, Juan J ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Alkaline phosphatase; Prostate cancer; Prostate specific antigen; Tumour markers

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; BONE TUMOR; CASE REPORT; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33644791289     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02716588     Document Type: Article

References (9)

1. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154:407-13.
2. Komatsu K, Wehner N, Prestigiacomo AF, Chen Z, Stamey TA. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology. 1996;47(3):343-6.
3. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16(2): 95-101.
4. Wolf SH. Screening for prostate cancer with prostate-specific antigen. N Engl J Med. 1995;333(21):1401-5.
5. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. JAMA. 1997;277(18):1452-5.
6. Krumholtz JS, Carvalhal GF, Ramos CG, et al. Prostatespecific antigen cut-off of 2.6 ng/ml for prostate cancer screening is associated with favourable pathologic tumor features. Urology. 2002;60(3):469-73.
7. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.
8. Balk SP, Yoo-Joung K, Bubley GJ. Biology of prostatespecific antigen. J Clin Oncol. 2003;21(2):383-91.
9. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88 12 Suppl:2919-26.